

Docket No. 210577US0SRD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mitsuko ISHIHARA, et al.

SERIAL NO: NEW APPLICATION

GAU:

FILED: Herewith

EXAMINER:

FOR: METHOD FOR DETECTING ENDOCRINE DISRUPTING ACTION OF A TEST SUBSTANCE

J1046 U.S. PTO
09/892485
06/28/01

INFORMATION DISCLOSURE/RELATED CASE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION


- ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Norman F. Oblon
Registration No. 24,618

C. Irvin McClelland
Registration Number 21,124



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/98)

Docket No. 210577US0SRD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mitsuko ISHIHARA, et al.

SERIAL NO: NEW APPLICATION

FILED: Herewith

FOR: METHOD FOR DETECTING ENDOCRINE DISRUPTING ACTION OF A TEST SUBSTANCE

GAU:

EXAMINER:

J1046 U.S. PTO
09/892485
06/28/01

INFORMATION DISCLOSURE/RELATED CASE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION


- ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Norman F. Oblon

Registration No. 24,618

C. Irvin McClelland
Registration Number 21,124



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/98)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mitsuko ISHIHARA, et al.

SERIAL NO.: New Application

FILED: Herewith

FOR: METHOD FOR DETECTING ENDOCRINE DISRUPTING ACTION OF A TEST
SUBSTANCE



STATEMENT OF RELEVANCY

Reference AA (4,859,585) on Form PTO-1449:

This discloses a method of detecting an estrogenic activity of chemicals. But this method can not detect various endocrine disrupter's toxicity except estrogenic toxicity.

Reference AO (2-79994) on Form PTO-1449:

This discloses a method of producing monoclonal antibody against oligosaccharide chain of glycoprotein. But this method can not provide monoclonal antibody binding specifically to the oligosaccharide chain altered by chemicals.

Reference AW on Form PTO-1449:

This reference shows that some candidate nucleotides for which expression were changed by 2-3-7-8-TCDD treatment were identified. But these cell culture for analysis do not contain normal hormones, ie., estrogen or T3.

Reference AX on Form PTO-1449:

This reference shows a method of detecting toxicity for chemicals by gene expressions. But this method can not detect toxicities caused by post translational modification.

Reference AY on Form PTO-1449:

This paper shows that tunicamycin, an antibiotic, affects oligosaccharide chain-structure of some glycoproteins. But this method can not detect effects of chemicals on oligosaccharide chains other than change of molecular weights.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 210577US0SRD		SERIAL NO. NEW APPLICATION	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Mitsuko ISHIHARA, et al.			
				FILING DATE Herewith		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	4,859,585	8/22/89	Carlos SONNENSCHNEIN, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO	2-79994	3/20/90	Japan			X
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	Sato WATANABE, et al., "Analysis of Gene Expression in 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD) -Treated Mouse Leydig Cells", Proceeding for Forum 2000; Pharmaceutical Health Science Environmental Toxicology (The Pharmaceutical Society of Japan), October 19, 2000, pgs. 135 & 136					
	AX	Hitoshi IWAHASHI, "Multi-endpoint Bioassay Using DNA Chip Technology", National Institute of Bioscience and Human-Technology, Vol. 58, No. 7, 2000, pgs. 481-484					
	AY	Guy SERVANT, et al., "Analysis of the Role of N-glycosylation in Cell-Surface Expression and Binding Properties of Angiotensin II Type-2 Receptor of Rat Pheochromocytoma Cells", Biochem. J., 1996, Vol. 313, pgs. 297-304					
	AZ						
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

